HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:

Vaniqa Rx Facial Hair Remover May Be Strong OTC Switch Candidate

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

Ongoing studies on Bristol-Myers Squibb's newly approved Vaniqa prescription hair removal drug could broaden the target consumer of the topical cream to include men. FDA approved the product for removal of women's facial hair July 27.
Table

View full table

Advertisement

Related Content

HBW Insight HBW Insight HBW Insight HBW Insight HBW Insight HBW Insight HBW Insight
Advertisement
Tags:
UsernamePublicRestriction

Register

RS008300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By